1952 related articles for article (PubMed ID: 23348694)
21. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo.
Yan S; Zhang H; Xie Y; Sheng W; Xiang J; Ye Z; Chen W; Yang J
Cancer Invest; 2010 Jan; 28(1):85-93. PubMed ID: 19916746
[TBL] [Abstract][Full Text] [Related]
23. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
24. A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
Chao TH; Tseng SY; Li YH; Liu PY; Cho CL; Shi GY; Wu HL; Chen JH
Clin Sci (Lond); 2012 Aug; 123(3):147-59. PubMed ID: 22339730
[TBL] [Abstract][Full Text] [Related]
25. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
Gu Y; Scheuer C; Feng D; Menger MD; Laschke MW
Anticancer Drugs; 2013 Sep; 24(8):781-91. PubMed ID: 23744558
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
28. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
29. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer.
Yuan Q; Cai S; Zhang X; Liu Z; Li Z; Luo X; Xiong C; Wang J; Hu J; Ruan J
Cancer Lett; 2012 Nov; 324(2):210-20. PubMed ID: 22652174
[TBL] [Abstract][Full Text] [Related]
30. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
31. Neuromedin B induces angiogenesis via activation of ERK and Akt in endothelial cells.
Park HJ; Kim SR; Bae SK; Choi YK; Bae YH; Kim EC; Kim WJ; Jang HO; Yun I; Kim YM; Bae MK
Exp Cell Res; 2009 Nov; 315(19):3359-69. PubMed ID: 19703440
[TBL] [Abstract][Full Text] [Related]
32. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
33. Intermedin: a novel regulator for vascular remodeling and tumor vessel normalization by regulating vascular endothelial-cadherin and extracellular signal-regulated kinase.
Zhang W; Wang LJ; Xiao F; Wei Y; Ke W; Xin HB
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2721-32. PubMed ID: 22922959
[TBL] [Abstract][Full Text] [Related]
34. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
[TBL] [Abstract][Full Text] [Related]
35. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
37. Osteogenesis and angiogenesis induced by porous β-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways.
Wang C; Lin K; Chang J; Sun J
Biomaterials; 2013 Jan; 34(1):64-77. PubMed ID: 23069715
[TBL] [Abstract][Full Text] [Related]
38. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
39. Thio-Cl-IB-MECA, a novel A₃ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells.
Kim GD; Oh J; Jeong LS; Lee SK
Biochem Biophys Res Commun; 2013 Jul; 437(1):79-86. PubMed ID: 23791876
[TBL] [Abstract][Full Text] [Related]
40. Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.
Chen ML; Lin YH; Yang CM; Hu ML
Mol Nutr Food Res; 2012 Jun; 56(6):889-99. PubMed ID: 22707264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
